ArticleBMC infectious diseases2025
Clinical utility of metagenomic next-generation sequencing (mNGS) and a novel PCR-based point-of-care testing (POCT) for pathogen detection in pulmonary infections: a retrospective study.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetagenomic next-generation sequencing (mNGS) and multiple point-of-care testing (POCT) techniques have demonstrated significant potential in pathogen detection. However, neither technology fully meets all clinical diagnostic needs for pulmonary infections. This study aimed to evaluate the complementary detection performance and clinical applicability of POCT and mNGS in pulmonary infections, using conventional culture as a reference.
methodsThis study enrolled forty-five patients with suspected lower respiratory tract infections for concurrent evaluation using POCT and mNGS. The detection performance of traditional culture methods, POCT, and mNGS was subsequently analyzed and compared.
resultsBoth molecular methods showed high positive detection rates, surpassing that of the culture method. When conventional culture was used as the gold standard, the sensitivity and positive predictive value (PPV) within the detection range of the PM Easy Lab Respiratory Panel (RP) were 97.1% and 80.5%, respectively, whereas for mNGS, these values were 90.2% and 92.5%, respectively. A comparison of the PM Easy Lab RP and mNGS results revealed that the PM Easy Lab was faster (100 min vs. 24 h) and more sensitive (88 vs. 63 pathogens) within its detection range, whereas mNGS offered a broader spectrum of pathogen detection. The overall consistency between PM Easy Lab RP and mNGS was 88.9%. Klebsiella pneumoniae and Acinetobacter baumannii were identified as the most prevalent bacterial infections by all three detection methods. Moreover, both PM Easy Lab RP and mNGS demonstrated enhanced capability over culture in detecting mixed infections (57.8%, 84.4% vs. 15.6%, all P < 0.01), uncovering a substantial number of viral and bacterial-viral co-infections that are undetectable by conventional culture methods. The most common combination of mixed infections in the PM Easy Lab RP was mixed bacterial infections (76.9%, 20/26), whereas in mNGS, it was bacterial-fungal-viral mixed infections (36.8%, 14/38).
conclusionsThe findings indicate that PM Easy Lab RP and mNGS offer distinct yet complementary value. PM Easy Lab has potential advantages in speed, sensitivity, and efficiency in detecting pathogens within its panel, and it could be considered for rapid, frontline testing, while mNGS provides a broad-spectrum detection capability, making it more suitable for comprehensive investigation of complex cases, though careful clinical interpretation is required to distinguish pathogenic from colonizing or contaminating organisms. Understanding their respective strengths can guide the development of optimized, hierarchical diagnostic pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.